ANAB

Daniel Faga

Known title: Interim CEOCIK: 0001673528

Associated companies

AI Market Commentary

AI-generatedAll commentary →

Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.

October 13, 2026

AnaptysBio News Mixes Valuation Views With Litigation Risks. Recent articles highlight a split in opinion on AnaptysBio. Some sources argue the stock is undervalued based on its royalty model, while others point to significant litigation uncertainty. This debate occurs as the stock has seen a substantial rise, though it currently trades near its 52-week high.

this person other insiders at ANAB

Transaction History

ANAB▼ Sell$63K
ANAB▼ Sell$164K
ANAB▼ Sell$203K
ANAB▼ Sell$198K
ANAB▼ Sell$7K
ANAB▼ Sell$29K
ANAB▼ Sell$149K
ANAB▼ Sell$215K
ANAB▼ Sell$29K
ANAB▼ Sell$33K
ANAB▲ Buy—
ANAB▼ Sell$639K
ANAB▲ Buy—
ANAB▼ Sell$415K
ANAB▲ Buy—
ANAB▼ Sell$662K
ANAB▲ Buy—
ANAB▲ Buy—
ANAB▼ Sell$98K
ANAB▲ Buy—
ANAB▼ Sell$190K
ANAB▼ Sell$7.5M
ANAB▼ Sell$64K
ANAB▼ Sell$3.3M
ANAB▼ Sell$150K
ANAB▲ Buy$0
ANAB▲ Buy$0

We use analytics to understand how market-wall is used. No personal data is sold.